Coronary Artery Bypass Graft surgery(CABG) has an important value in the management of patients with coronary or valvular heart disease. Because of increasing the interest to perform less invasive interventions in these patients, CABG is now performed for patients with higher comorbidities and more severe cases having more post operative complications1. Thus, clinical risk stratification has a great role in preoperative evaluation of patients undergoing CABG2. Electrocardiography, hemodynamic parameters, biochemical markers like creatinin kinase (CK), myoglobulin creatinin kinase (CK-MB) and troponins and transthoracic/transesophageal echocardiography are routinely used for the diagnosis of preoperative cardiac problems and prediction of perioperative comorbidities3. BNP is secreted by ventricular myocytes due to increased ventricular wall tension related to volume expansion. BNP is a simple blood test, which can easily be performed in most biochemistry laboratories as part of a routine preoperative assessment. Previous studies showed that increased level of preoperative BNP is associated with higher morbidities and mortality after cardiac surgeries4-6. Postoperative BNP has the potential to show the preoperative condition of heart and cardiac injury induced by surgical intervention but its value as a prognostic marker has not been largely evaluated7,8.
Totonchi et al evaluated the association of preoperative and post operative BNP with morbidity in 50 adult patients who were scheduled for elective CABG in Tehran Shahid Rajaie heart center from Sep 2016 to May 2017. Patients with emergency situations, hematocrit less than 25 and patients on inotropic therapy were excluded. Samples were taken for BNP levels 24 hours pre and post operative. They showed that perioperative BNP didn’t have any correlation with other comorbidities and major complications after cardiac surgeries except for ejection fraction. Their results showed that patients with higher perioperative BNP levels had significantly higher risk factor for low ejection fraction and heat failure after CABG9. Fox and coworkers in their prospective longitudinal study of 1,183 patients undergoing primary coronary artery bypass grafting surgery, compared the utility of preoperative with postoperative BNP for predicting hospital LOS and mortality after primary PCI. After multivariable adjustment for preoperative BNP and clinical covariates, peak postoperative BNP predicted hospital LOS (hazard ratio [HR] = 1.28, 95% CI = 1.002-1.64, P = 0.049) but not mortality. Whereas preoperative BNP independently predicted hospital LOS (HR = 1.09, CI = 1.01-1.18, P = 0.03) and was defined as an independent predictor of mortality (HR = 1.36, CI = 0.96-1.94, P = 0.08). When preoperative and peak postoperative BNP were separately adjusted for the clinical multivariable models, each independently predicted hospital LOS and mortality10. Previous studies showed that post operative BNP levels which measured 24 hours after surgery did not significantly predict adverse cardiovascular events and peak post operative BNP measurement should be considered as a surrogate for cardiovascular complications. Peak postoperative BNP tends to occur later in the postoperative course, around day 3 or 5.
The study of Totonchi et al has some major limitations. It has been performed in a single center which has inherent limitations. The study’s HF outcome did not delineate specific etiologies of observed postoperative HF events (e.g., systolic vs. diastolic dysfunction or left atrial enlargement). BNP has been affected by kidney function and pulmonary disease but patients with kidney and lung disease were enrolled in this study. Moreover, the authors didn’t perform long term follow up after discharge. The authors measured BNP by electrochemiluminescence immunoassay, which measures only nonglycoNT-proBNP. This method understimates the BNP level compared to NT-proBNP assay system currently being used. Therefore, careful interpretation of the BNP levels and clinical application may be required. Finally, the authors didn’t use logistic regression analysis for adjustment of clinical risk factors; so, interpreting and globalization of these results is not possible.
Based on literature review, there is little added benefit to measure postoperative BNP either instead of or in combination with preoperative BNP. So, it seems that we do not need to measure both preoperative and postoperative BNP together for the purposes of risk stratifying of CABG patients. But if preoperative BNP measurement is not possible, we can use peak post operative BNP measurement for prediction of major cardiovascular complications. Patients at high risk should be considered for less invasive procedures and must receive optimized perioperative care. Further research with a larger number of patients having various types of surgeries and good methodologic design is needed to confirm the clinical utility of this prognostic test.
-Cuthbertson BH, Croal BL, Rae D, Harrild K, Gibson PH, Prescott GJ, Kengne AP, Hillis GS. N-terminal pro-B-type natriuretic peptide concentrations and longterm outcome after cardiac surgery: a prospective cohort study. Br J Anaesth. 2013 Feb; 110(2):214-21.
- Ma J, Xin Q, Wang X, Gao M, Wang Y, Liu J. Prediction of perioperative cardiac events through preoperative NT-pro-BNP and cTnI afteremergent non-cardiac surgery in elderly patients. PLoS One. 2015 Mar 23;10(3):e0121306.
- Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
- Gibson PH, Croal BL, Cuthbertson BH, Rae D, McNeilly JD, Gibson G, Jeffrey RR, Buchan KG, El-Shafei H, Hillis GS. Use of preoperative natriuretic peptides and echocardiographic parameters in predicting new-onset atrial fibrillation after coronary artery bypass grafting: A prospective comparative study. Am Heart J. 2009; 158:244–51.
-Fox AA, Shernan SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, Jarolim P, Body SC. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008; 136:452– 61.
- Hutfless R, Kazanegra R, Madani M, Bhalla MA, Tulua-Tata A, Chen A, Clopton P, James C, Chiu A, Maisel AS. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol. 2004; 43:1873–9
- Nozohoor S, Nilsson J, Luhrs C, Roijer A, Algotsson L, Sjogren J. B-type natriuretic peptide as a predictor of postoperative heart failure after aortic valve replacement. J Cardiothorac Vasc Anesth. 2009; 23:161–5.
- Fellahi JL, Hanouz JL, Manach YL, Gue X, Monier E, Guillou L, Riou B. Simultaneous measurement of cardiac troponin I, B-type natriuretic peptide, and C-reactive protein for the prediction of long-term cardiac outcome after cardiac surgery. Anesthesiology. 2009; 111:250–7.
- Totonchi MZ, Forouzeshfar M, Fani K, Salajeghe S, Ghoreishi M. Association of preoperative and postoperative Brain Natriuretic Peptide hormone with morbidity in adult patients undergoing Coronary Artery Bypass Graft surgery. Journal of Cellular & Molecular Anesthesia. 2019; 3(4): 129-
- Fox AA, Muehlschlegel JD, Body SC, Shernan SK, Liu KY, Perry TE, et al.Comparison of the utility of preoperative versus postoperative Btype natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting.Anesthesiology. 2010 Apr;112(4):842-51.